Successful ombitasvir/paritaprevir/ritonavir plus ribavirin retreatment for a chronic hepatitis c genotype 2a patient who relapsed after sofosbuvir plus ribavirin treatment

Abstract

The optimum retreatment strategy for chronic hepatitis C virus (HCV) patients who failed directly-acting antiviral agents (DAA)-based therapy is unknown. We herein report the outcomes of an HCV genotype (GT) 2a-infected patient with virologic failure following treatment with sofosbuvir plus ribavirin (SOF+RBV) who was successfully retreated with ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV).